Ascletis Advances ASC30 Phase II Trial in Diabetes

Hong Kong | April 27, 2026

Ascletis Pharma Inc. has announced the successful completion of enrollment in its U.S. Phase II clinical trial evaluating ASC30, a novel oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). This milestone represents a significant step in the company’s strategy to expand ASC30’s clinical potential beyond obesity into the rapidly growing global diabetes therapeutics market, with topline results expected in Q3 2026.

Oral GLP-1 Innovation Targets Expanding Diabetes Market

ASC30 is positioned as a next-generation, once-daily oral GLP-1R agonist, offering a potential alternative to injectable therapies currently dominating the diabetes and obesity treatment landscape. As a fully biased small molecule GLP-1 receptor agonist, ASC30 is uniquely designed to deliver enhanced efficacy and improved tolerability, addressing key limitations associated with traditional peptide-based GLP-1 therapies.

The global burden of type 2 diabetes continues to rise, driving demand for convenient, effective, and patient-friendly treatment options. Oral therapies like ASC30 have the potential to transform patient adherence and accessibility, particularly for individuals who prefer non-injectable regimens.

ASC30’s development is further strengthened by its dual therapeutic positioning, with prior Phase II data in obesity and overweight patients demonstrating promising efficacy and safety profiles. This positions ASC30 as a potential best-in-class candidate across multiple metabolic indications, including diabetes, obesity, and related disorders.

Robust Phase II Study Design and Clinical Endpoints

The 13-week randomized, double-blind, placebo-controlled Phase II trial enrolled 100 participants across multiple U.S. clinical sites, evaluating the efficacy, safety, and tolerability of ASC30 tablets at varying dose levels. The study’s primary endpoint focuses on reduction in HbA1c levels, a critical biomarker for long-term glycemic control in diabetes patients.

Secondary endpoints include changes in fasting blood glucose, body weight, and overall safety outcomes, providing a comprehensive assessment of ASC30’s therapeutic potential. Participants were randomized across multiple dosing regimens (40 mg, 60 mg, and 80 mg), enabling detailed analysis of dose-response relationships and optimal therapeutic dosing strategies.

The study design reflects rigorous clinical standards, ensuring high-quality data that can support future regulatory submissions and late-stage development. The anticipated topline results in Q3 2026 are expected to provide key insights into ASC30’s efficacy in glucose control and metabolic improvement, potentially validating its role as a competitive oral GLP-1 therapy.

Pipeline Expansion and Strategic Growth in Metabolic Diseases

Ascletis Pharma Inc. continues to leverage its proprietary drug discovery platforms, including AI-assisted structure-based design and ultra-long-acting technologies, to advance a diversified pipeline of metabolic disease therapies. In addition to ASC30, the company is developing multiple candidates targeting GLP-1, GIP, and amylin receptors, reflecting a multi-targeted approach to metabolic disease management.

The company has also indicated plans to initiate Phase III trials for ASC30 in obesity by late 2026, pending regulatory clearance, further strengthening its position in the high-growth obesity and diabetes markets. This dual-indication strategy highlights ASC30’s potential as a versatile, scalable therapeutic solution addressing multiple aspects of metabolic dysfunction.

From a broader industry perspective, the development of oral small molecule GLP-1 therapies represents a significant shift toward more accessible and patient-centric treatment paradigms, reducing reliance on injectables and improving long-term adherence.

As the diabetes epidemic continues to expand globally, innovations like ASC30 are poised to play a crucial role in improving clinical outcomes, enhancing patient convenience, and reducing healthcare burden. The completion of enrollment in this Phase II study marks a critical milestone in Ascletis’ journey toward delivering next-generation metabolic therapies, with the potential to reshape the future of diabetes and obesity treatment.

Source: Ascletis Pharma press release